<?xml version="1.0" encoding="UTF-8"?>
<rr:ResultsReport xmlns:rr="http://integration.foundationmedicine.com/reporting" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd">
  <rr:CustomerInformation>
    <rr:ReferenceID>01-2024-00036761</rr:ReferenceID>
    <rr:CSN />
    <rr:TRF>ORD-1795940-01</rr:TRF>
    <rr:MRN>27711633</rr:MRN>
    <rr:PhysicianId>109266</rr:PhysicianId>
    <rr:NPI />
  </rr:CustomerInformation>
  <rr:ResultsPayload>
    <FinalReport xmlns:xsd="http://www.w3.org/2001/XMLSchema" StagingId="1440768" clinicalId="1442068" xsi:noNamespaceSchemaLocation="http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd">
      <Application>
        <ApplicationSettings>
          <ApplicationSetting>
            <Name>Statement</Name>
            <Value />
          </ApplicationSetting>
        </ApplicationSettings>
      </Application>
      <DemographicCorrectionDate />
      <ReportId>ORD-1795940-01</ReportId>
      <SampleName>US1710200.01</SampleName>
      <Version>0</Version>
      <Sample>
        <FM_Id>ORD-1795940-01</FM_Id>
        <SampleId>US1710200.01</SampleId>
        <BlockId>S113-00200U (PF24006)</BlockId>
        <TRFNumber>ORD-1795940-01</TRFNumber>
        <TestType>FoundationOne CDX</TestType>
        <SpecFormat>Slide Deck</SpecFormat>
        <ReceivedDate>2024-01-10</ReceivedDate>
        <processSites>
          <processSite address="150 Second St., 1st Floor, Cambridge, MA 02141" cliaNumber="22D2027531" locationID="1" locationName="Cambridge" processID="1" processName="Extracted DNA" />
          <processSite address="150 Second St., 1st Floor, Cambridge, MA 02141" cliaNumber="22D2027531" locationID="1" locationName="Cambridge" processID="1" processName="LC" />
        </processSites>
      </Sample>
      <PMI>
        <ReportId>ORD-1795940-01</ReportId>
        <MRN>27711633</MRN>
        <FullName>Yeh, Hsiu-Chin</FullName>
        <FirstName>Hsiu-Chin</FirstName>
        <LastName>Yeh</LastName>
        <SubmittedDiagnosis>Peritoneum serous carcinoma</SubmittedDiagnosis>
        <Gender>Female</Gender>
        <DOB>1970-02-12</DOB>
        <OrderingMD>Yeh, Yi-Chen</OrderingMD>
        <OrderingMDId>109266</OrderingMDId>
        <Pathologist>Not Provided</Pathologist>
        <CopiedPhysician1 />
        <MedFacilName>Taipei Veterans General Hospital</MedFacilName>
        <MedFacilID>205872</MedFacilID>
        <SpecSite>Omentum</SpecSite>
        <CollDate>2024-01-03</CollDate>
        <ReceivedDate>2024-01-10</ReceivedDate>
        <CountryOfOrigin>TW</CountryOfOrigin>
      </PMI>
      <PertinentNegatives>
        <PertinentNegative>
          <Gene>BRCA1</Gene>
        </PertinentNegative>
        <PertinentNegative>
          <Gene>BRCA2</Gene>
        </PertinentNegative>
      </PertinentNegatives>
      <Summaries alterationCount="17" clinicalTrialCount="12" resistiveCount="0" sensitizingCount="4" />
      <VariantProperties>
        <VariantProperty geneName="ARAF" isVUS="true" variantName="E578D" />
        <VariantProperty geneName="AURKB" isVUS="true" variantName="R81C" />
        <VariantProperty geneName="BRD4" isVUS="true" variantName="V228I" />
        <VariantProperty geneName="CHEK1" isVUS="true" variantName="amplification" />
        <VariantProperty geneName="EGFR" isVUS="true" variantName="M1?" />
        <VariantProperty geneName="KDM5C" isVUS="true" variantName="P1365L" />
        <VariantProperty geneName="KDM6A" isVUS="true" variantName="C579Y" />
        <VariantProperty geneName="KMT2A (MLL)" isVUS="true" variantName="V3248fs*5" />
        <VariantProperty geneName="KMT2D (MLL2)" isVUS="true" variantName="P4048L" />
        <VariantProperty geneName="NTRK1" isVUS="true" variantName="M566T" />
      </VariantProperties>
      <priorTests />
      <Genes>
        <Gene>
          <Name>Loss of Heterozygosity score</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>LOH-High</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="LOH-High" />
              </AlterationProperties>
              <Interpretation>The loss of heterozygosity (LOH) score is a profile of the percentage of the tumor genome that is under focal loss of one allele (Swisher et al., 2016; 27908594); focal LOH events accumulate as genomic "scars" as a result of incorrect DNA double-strand break repair when the homologous recombination pathway is deficient (HRD) (Abkevich et al., 2012; 23047548, Wang et al., 2012; 22912389, Watkins et al., 2014; 25093514, Vanderstichele et al., 2017; 28950147). HRD and consequent genomic LOH occur as a result of genetic or epigenetic inactivation of one or more of the homologous recombination pathway proteins, including BRCA1, BRCA2, RAD51C, ATM, PALB2, and BRIP1 (Vanderstichele et al., 2017; 28950147, Watkins et al., 2014; 25093514, Cancer Genome Atlas Research Network., 2011; 21720365, Venkitaraman, 2003; 12736286). This sample harbors a genomic LOH score that has been shown to be associated with sensitivity to the PARP inhibitor rucaparib in platinum-sensitive, BRCA1/2 wild-type ovarian, peritoneal, or Fallopian tube carcinoma in both the treatment (Coleman et al., 2016; ASCO Abstract 5540, Swisher et al., 2016; 27908594) and maintenance (Coleman et al., 2017; 28916367) settings. In a study of more than 4,000 ovarian, Fallopian tube, or peritoneal cancer samples, genomic LOH score ≥ 16% was identified in 24.2% of BRCA1/2 wild-type cases, deleterious BRCA1/2 mutation was identified in an additional 17.2% of cases, and the remaining 58.7% of cases had LOH score &lt; 16% and were BRCA1/2 wild-type (Elvin et al., 2017; ASCO Abstract 5512). Among the histological subtypes, LOH score ≥ 16% or BRCA1/2 mutation was reported in 42.4% of serous carcinomas, 37.6% of endometrioid carcinomas, 23.5% of carcinosarcomas, 20.6% of neuroendocrine carcinomas, 13.6% of clear cell carcinomas, and 8.1% of mucinous carcinomas; in BRCA1/2 wild-type samples, the median LOH score was significantly higher in serous as compared with non-serous cases (Elvin et al., 2017; ASCO Abstract 5512). In ovarian carcinoma, the median LOH score is significantly higher for BRCA1/2-mutated cases than BRCA1/2 wild-type cases (22.2% vs. 9.8%) (Elvin et al., 2017; ASCO Abstract 5512), and mutation or methylation of BRCA1, BRCA2, or RAD51C has been reported to be enriched in cases with increased genomic LOH (Wang et al., 2012; 22912389, Abkevich et al., 2012; 23047548). One study reported no association between LOH and either tumor stage or grade in ovarian serous carcinoma (Marquard et al., 2015; 26015868). In patients with high-grade serous ovarian carcinoma, the frequency of LOH has been reported to increase significantly with age (Pedersen et al., 2013; 23716468). On the basis of emerging clinical data in ovarian cancer, elevated genomic LOH may be associated with greater sensitivity to PARP inhibitors (Coleman et al., 2016; ASCO Abstract 5540, Coleman et al., 2017; 28916367, Swisher et al., 2016; 27908594). In platinum-sensitive, BRCA1/2 wild-type ovarian, peritoneal, or Fallopian tube carcinoma, rucaparib elicited significantly longer median PFS (7.2 vs. 5.0 months, HR=0.51) and improved ORR (33.3% vs. 9.6%, p=0.0003) for patients with LOH score ≥ 16% (Coleman et al., 2016; ASCO Abstract 5540, Swisher et al., 2016; 27908594). In the maintenance setting in platinum-sensitive, BRCA1/2 wild-type patients, rucaparib was superior to placebo in both the LOH score ≥ 16% (median PFS, 9.7 vs. 5.4 months; HR=0.44) and LOH score &lt; 16% (median PFS, 6.7 vs. 5.4 months; HR=0.58) cohorts (Coleman et al., 2017; 28916367). Similar results have been reported for maintenance treatment with niraparib in ovarian cancer (Mirza et al., 2016; 27717299) when using a different measure of HRD that includes genomic LOH (Telli et al., 2016; 26957554, Timms et al., 2014; 25475740). Increased LOH has also been associated with improved sensitivity to platinum-containing chemotherapy regimens in patients with ovarian or breast cancer (Wang et al., 2012; 22912389, Telli et al., 2015; 25847929, Isakoff et al., 2015; 25847936).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote>On the basis of emerging clinical data in ovarian cancer, elevated genomic LOH may be associated with greater sensitivity to PARP inhibitors.</ClinicalTrialNote>
              <Therapies>
                <Therapy>
                  <Name />
                  <GenericName>Niraparib</GenericName>
                  <FDAApproved>true</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; The PARP inhibitor niraparib is FDA approved to treat patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, with or without homologous recombination deficiency (HRD)-positive status. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of emerging clinical data in ovarian cancer, elevated genomic LOH may be associated with greater sensitivity to PARP inhibitors (Coleman et al., 2016; ASCO Abstract 5540, Coleman et al., 2017; 28916367, Swisher et al., 2016; 27908594). In platinum-sensitive, BRCA1/2 wild-type ovarian, peritoneal, or Fallopian tube carcinoma, the PARP inhibitor rucaparib elicited significantly longer median PFS and improved ORR for patients with LOH score ≥ 16% (Coleman et al., 2016; ASCO Abstract 5540, Swisher et al., 2016; 27908594). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; For patients with platinum-sensitive, recurrent ovarian cancer (OC), the Phase 3 ENGOT-OV16/NOVA study showed that niraparib maintenance therapy significantly increased median PFS (mPFS) relative to placebo, regardless of germline BRCA (gBRCA) mutation (21.0 vs. 5.5 months, HR=0.27 for patients with gBRCA mutations; 9.3 vs. 3.9 months, HR=0.45 for patients without gBRCA mutations) or homologous recombination deficiency (HDR) status (12.9 vs. 3.8 months, HR=0.38) (Mirza et al., 2016; 27717299, Fabbro et al., 2019; 30638768). Similarly, the Phase 3 PRIMA trial for patients with newly diagnosed advanced OC reported an extended mPFS from niraparib maintenance therapy after response to first-line platinum chemotherapy compared with placebo (13.8 vs. 8.2 months, HR=0.62); subgroup analysis showed that patients with HRD-positive OC experienced the longest mPFS, which was irrespective of BRCA mutational status (21.9 vs. 10.4 months, HR=0.43) (Gonzalez-Martin et al., 2019; 31562799). The Phase 2 QUADRA study evaluating niraparib monotherapy as late-line treatment for patients with relapsed high-grade serous epithelial ovarian cancer (HGSOC) reported a median OS (mOS) of 12.2 months for all HGSOC patients, with highest mOS seen for those with BRCA1/2-mutated and HRD-positive tumors (26.0 and 19.0 months, respectively) (Moore et al., 2019; 30948273). A Phase 2 trial for patients with platinum-sensitive HGSOC and endometrioid recurrent ovarian cancer reported significantly improved mPFS from the addition of bevacizumab to niraparib compared with niraparib alone (11.9 vs. 5.5 months, HR=0.35) (Mirza et al., 2019; 31474354). In a Phase 1/2 study of niraparib in combination with pembrolizumab for patients with recurrent platinum-resistant OC, patients experienced an ORR of 19% (11/59) and mPFS of 3.4 months; no significant differences in ORR were noted among analyzed subgroups: 14% (3/21) versus 19% (6/32) for patients with HRD-positive versus HRD-negative tumors, 18% (2/11) versus 19% (9/47) for patients with BRCA-mutated versus BRCA-wildtype tumors, and 21% (7/33) versus 10% (2/21) for patients with PD-L1-positive versus PD-L1-negative tumors (Konstantinopoulos et al., 2019; 31194228). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Olaparib</GenericName>
                  <FDAApproved>true</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; The PARP inhibitor olaparib is FDA approved to treat patients with epithelial ovarian, Fallopian tube, or primary peritoneal cancer, patients with deleterious or suspected deleterious gBRCA-mutated pancreatic adenocarcinoma or HER2-negative breast cancer, and patients with prostate cancer and mutations in homologous recombination repair genes. Olaparib is also approved in combination with bevacizumab to treat patients with ovarian, Fallopian tube, or primary peritoneal cancer with deleterious or suspected deleterious somatic or gBRCA mutation and/or genomic instability. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of emerging clinical data in ovarian cancer, elevated genomic LOH may be associated with greater sensitivity to PARP inhibitors (Coleman et al., 2016; ASCO Abstract 5540, Coleman et al., 2017; 28916367, Swisher et al., 2016; 27908594). In platinum-sensitive, BRCA1/2 wild-type ovarian, peritoneal, or Fallopian tube carcinoma, the PARP inhibitor rucaparib elicited significantly longer median PFS and improved ORR for patients with LOH score ≥ 16% (Coleman et al., 2016; ASCO Abstract 5540, Swisher et al., 2016; 27908594). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; Olaparib has been studied primarily to treat patients with ovarian cancer harboring BRCA1/2 mutations. Numerous Phase 2 studies have demonstrated significant clinical activity for patients with BRCA-mutated ovarian cancer, with response rates often significantly higher for patients with BRCA mutations than for those without (Fong et al., 2009; 19553641, Gelmon et al., 2011; 21862407) and for patients with platinum-sensitive (vs. platinum resistant) cancer (Domchek et al., 2016; 26723501, Matulonis et al., 2016; 26961146, Gelmon et al., 2011; 21862407, Fong et al., 2010; 20406929). As maintenance therapy for patients with newly diagnosed or platinum-sensitive relapsed ovarian cancer, olaparib monotherapy demonstrated significantly improved OS and median PFS (mPFS) compared with placebo in the Phase 3 SOLO-1 study (Moore et al., 2018; 30345884) and multiple later-phase studies (Poveda et al., 2021; 33743851, Pujade-Lauraine et al., 2017; 28754483, Ledermann et al., 2016; 27617661, Ledermann et al., 2012; 22452356, Ledermann et al., 2014; 24882434). At the 7-year follow-up of SOLO-1, olaparib continued to improve mPFS compared with placebo for patients with ovarian cancer (DiSilvestro et al., 2022; 36082969), and mOS was not reached for olaparib compared with 75.2 months for placebo (HR=0.55) (DiSilvestro et al., 2022; ESMO Abstract 517O). In the first study of PARP inhibitor rechallenge for patients with ovarian cancer, the Phase 3 OReO/ENGOT Ov-38 study of maintenance olaparib compared with placebo reported statistically improved mPFS for both patients with BRCA-mutated (4.3 vs. 2.8 months, HR=0.57) and BRCA-unmutated (5.3 vs. 2.8 months, HR=0.43) cancer; in an exploratory analysis of the BRCA-unmutated cohort, improved mPFS was reported regardless of homologous recombination deficiency status (Pujade-Lauraine et al., 2021; ESMO Abstract LBA33). The Phase 4 ORZORA trial confirmed the efficacy of olaparib as maintenance therapy for platinum-sensitive relapsed ovarian cancer after ≥2 lines of treatment, with an mPFS of 16.6 months for patients with somatic BRCA mutations (n=35) and of 19.3 months for those with germline BRCA mutations (n=52) (Pignata et al., 2023; 37030280). Olaparib has been evaluated in combination with other therapies. A statistically superior median PFS (mPFS) from treatment with olaparib in combination with the VEGF inhibitor bevacizumab compared with bevacizumab monotherapy was reported in the Phase 3 PAOLA-1 study for patients with newly diagnosed advanced ovarian cancer in the intent-to-treat population (22.1 vs. 16.6 months, HR=0.59), in the population with BRCA1/2 mutations (37.2 vs. 21.7 months, HR=0.31), and in the population with wildtype BRCA1/2 harboring homologous recombination deficiency (HRD)-positive status (28.1 vs. 16.6 months, HR=0.43); however, no significant difference in mPFS was reported in the population with mutations in non-BRCA genes involved in homologous recombination repair (HRR) (16.8-22.1 vs. 16.6-27.0 months, HR=0.95-1.83) (Ray-Coquard et al., 2019; 31851799, Pujade-Lauraine et al., 36716415). The final OS analysis for this trial reported benefit from the maintenance treatment using olaparib plus bevacizumab versus bevacizumab alone for patients with HRD-positive status (65.5 vs. 48.4 months), patients with HRD-positive status and BRCA1/2 mutations (73.2 vs. 53.8 months), and patients with HRD-positive status without BRCA1/2 mutations (54.7 vs. 44.2 months) (Ray-Coquard et al., 2022; ESMO Abstract LBA29). For patients with platinum-sensitive recurrent ovarian cancer who previously progressed on chemotherapy, statistically increased mPFS was reported in a Phase 2 study of olaparib in combination with chemotherapy (12.2 months) compared with chemotherapy alone (9.6 months) (Oza et al., 2014; 25481791), as well as from treatment with the VEGFR inhibitor cediranib compared with olaparib monotherapy in a Phase 1/2 trial (Liu et al., 2014; 25218906). Combination treatment with cediranib and olaparib also demonstrated numerically longer mPFS compared with chemotherapy alone for patients with BRCA1/2-mutated platinum-sensitive recurrent ovarian cancer (10.5 vs. 18 months); however, improved clinical benefit was not observed for patients without BRCA1/2 mutation (mPFS of 9.7 vs. 8.9 months) or for the overall intent-to-treat population (mPFS of 10.3 vs. 10.4 months, ORR of 71% vs. 69%) (Liu et al., 2022; 35290101). The Phase 2 CAPRI study for PARP inhibitor-resistant patients with HRD platinum-sensitive high-grade ovarian cancer treated with combination therapy of olaparib and the ATR inhibitor ceralasertib reported an ORR of 46% (n=13, 6 PRs) and a PFS of 7.5 months (Wethington et al., 2021; ASCO Abstract 5516). For patients with PARP-resistant ovarian cancer, the combination of olaparib and the WEE1 inhibitor adavosertib elicited improved clinical benefit (ORR 29%, DCR 89%) compared with adavosertib alone (ORR 23%, DCR 63%); however, in the BRCA-mutated cohort, no significant difference in clinical benefit was observed between the combination (ORR 19%) and monotherapy (ORR 20%) treatments (Westin et al., 2021; ASCO Abstract 5505). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Talazoparib</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; The PARP inhibitor talazoparib is FDA approved to treat HER2-negative locally advanced or metastatic breast cancer with deleterious or suspected deleterious germline BRCA mutations. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of emerging clinical data in ovarian cancer, elevated genomic LOH may be associated with greater sensitivity to PARP inhibitors (Coleman et al., 2016; ASCO Abstract 5540, Coleman et al., 2017; 28916367, Swisher et al., 2016; 27908594). In platinum-sensitive, BRCA1/2 wild-type ovarian, peritoneal, or Fallopian tube carcinoma, the PARP inhibitor rucaparib elicited significantly longer median PFS and improved ORR for patients with LOH score ≥ 16% (Coleman et al., 2016; ASCO Abstract 5540, Swisher et al., 2016; 27908594). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; An ORR of 42% (5/12) was reported for patients with BRCA1/2-mutated ovarian cancer treated with talazoparib in a Phase 1 study (deBono et al., 2017; 28242752). In a Phase 2 study of talazoparib in advanced solid tumors, 1 patient with BRIP1-mutated ovarian carcinoma with wildtype BRCA status experienced a prolonged SD (Piha Paul et al., 2018; AACR abstract A096). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Rucaparib</GenericName>
                  <FDAApproved>true</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; The PARP inhibitor rucaparib is FDA approved to treat patients with metastatic castration-resistant prostate cancer (mCRPC) and deleterious somatic or germline BRCA mutations. Rucaparib is also approved as a maintenance treatment of patients with recurrent epithelial ovarian, Fallopian tube, or primary peritoneal cancer. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of emerging clinical data in ovarian cancer, elevated genomic LOH may be associated with greater sensitivity to PARP inhibitors (Coleman et al., 2016; ASCO Abstract 5540, Coleman et al., 2017; 28916367, Swisher et al., 2016; 27908594). In platinum-sensitive, BRCA1/2 wild-type ovarian, peritoneal, or Fallopian tube carcinoma, the PARP inhibitor rucaparib elicited significantly longer median PFS and improved ORR for patients with LOH score ≥ 16% (Coleman et al., 2016; ASCO Abstract 5540, Swisher et al., 2016; 27908594). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; As first-line maintenance therapy evaluated in the Phase 3 ATHENA study, rucaparib monotherapy significantly improved median PFS (mPFS) compared with placebo for patients with ovarian cancer in both the homologous recombination deficient (HRD)-positive population (BRCA mutated or BRCA wildtype and high genomic loss of heterozygosity [LOH] score defined as ≥16%; mPFS of 28.7 vs. 11.3 months, HR=0.47) and the overall population (mPFS of 20.2 vs. 9.2 months, HR=0.52); exploratory subgroup analysis also reported benefit for the HRD-negative group (BRCA wildtype and low genomic LOH score defined as &lt;16%; mPFS of 12.1 vs. 9.1 months, HR=0.65) (Monk et al., 2022; 35658487). In the Phase 3 ARIEL3 study of rucaparib maintenance treatment for patients with recurrent platinum-sensitive high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube carcinoma, mPFS was significantly improved with rucaparib compared with placebo for patients, irrespective of HRD or BRCA status, with benefit observed for both the LOH-high subgroup (13.6 vs. 5.4 months, HR=0.32) and the overall population (10.8 vs. 5.4 months, HR=0.36), with CR rates of 12% for the HRD-positive group and 7% for the overall population; PFS benefit was also observed for the BRCA-wildtype, LOH-low group (HR=0.58) (Coleman et al., 2017; 28916367). In the Phase 2 ARIEL2 trial for patients with recurrent platinum-sensitive ovarian, peritoneal, or fallopian tube carcinoma, mPFS on rucaparib was 5.7 months for patients with high LOH and 5.2 months for patients with low LOH (Swisher et al., 2016; 27908594). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
              </Therapies>
              <ReferenceLinks />
              <ClinicalTrialLinks>
                <ClinicalTrialLink nctId="NCT05489211">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04434482">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05797168">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04884360">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04518501">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05489926">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT03983226">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04586335">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT03742895">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT02264678">
                  <Include>true</Include>
                </ClinicalTrialLink>
              </ClinicalTrialLinks>
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>TP53</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>R196*</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="62.04" isEquivocal="false" name="R196*" />
              </AlterationProperties>
              <Interpretation>Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 alterations have been reported in all subtypes of ovarian tumors; generally, high grade serous tumors are associated with greater frequency of TP53 alteration (&gt;80%), while low grade serous and clear cell ovarian tumors are infrequently associated with TP53 alteration (&lt;10%). The MSK-METropism study reported TP53 alterations in 96% of high grade serous ovarian cancers versus 1% in low grade serous and 15% of clear cell carcinomas, similar to trends reported across earlier studies (Nguyen et al., 2022; 35120664, Ahmed et al., 2010; 20229506, Wojnarowicz et al., 2012; 23029043, Karst and Drapkin, 2010; 19746182, Gadducci et al., 2012; 22304686, Cancer Genome Atlas Research Network, 2011; 21720365, Rechsteiner et al., 2013; 23965232, McConechy et al., 2014; 23765252, Sugino et al., 2019; 3178070). Similarly, multiple genomic studies of ovarian mucinous neoplasms reported TP53 mutations in 12-18% of benign or borderline tumors and in 52-64% of carcinomas (Ryland et al., 2015; 26257827, Cheasley et al., 2019; 31477716). In endometrioid carcinomas, TP53 mutations were reported in 26% of cases in a genomic study (Hollis et al., 2020; 33020491). Aberrant p53 expression has been associated with higher ovarian serous carcinoma grade (89-90% of high-grade vs. 6.6-9% of low-grade vs. 0% of benign) (Altman et al., 2013; 23558569, Giurgea et al., 2012; 23303020, Rajesh et al., 2007; 17883046). In one study, p53 expression was not prognostic in regard to outcome in patients with peritoneum serous carcinoma (Lee et al., 2013; 24071870). TP53 mutations have been reported to be more frequent in advanced stage (63%, 55/87) and higher grade (65%, 42/64) than earlier stage (31%, 14/45) and lower grade (41%, 7/17) ovarian carcinomas (Rechsteiner et al., 2013; 23965232). Meta-analysis has suggested that TP53 expression was associated with poorer survival in ovarian epithelial cancers, although the effect was modest and considerable variability was observed between studies (de Graeff et al., 2009; 19513073). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633) or p53 gene therapy such as SGT53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628, Leung et al., 2021; ASCO Abstract 4139). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). Phase 2 studies of adavosertib in combination with chemotherapy reported ORRs of 32% (30/94) and 41% (12/29) for patients with platinum-refractory TP53-mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513, Embaby et al., 2023; 37236033). For patients with platinum-sensitive TP53-mutated ovarian cancer, the combination of adavosertib with paclitaxel and carboplatin significantly increased PFS compared with paclitaxel and carboplatin alone (9.9 vs. 8.0 months) (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53-mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4-C trial for patients with TP53- and RAS-mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT-53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53-positive high-grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29) (Park et al., 2022; 36084396). One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li-Fraumeni syndrome (ClinVar, Sep 2023)(Landrum et al., 2018; 29165669). Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li-Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna-Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote>TP53 loss of function alterations may predict sensitivity to WEE1 inhibitors.</ClinicalTrialNote>
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks>
                <ClinicalTrialLink nctId="NCT04516447">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT03968653">
                  <Include>true</Include>
                </ClinicalTrialLink>
              </ClinicalTrialLinks>
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>CDKN2A/B</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>p16INK4a loss exon 1</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="p16INK4a loss exon 1" />
              </AlterationProperties>
              <Interpretation>CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth-suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6-cyclin-Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). CDKN2A mutation has been observed in &lt;1% of peritoneal tumors analyzed in the COSMIC database (Jan 2023)(Tate et al., 2019; 30371878). In the Ovarian Serous Cystadenocarcinoma TCGA dataset, CDKN2A/B loss has been reported in 2.2% of cases, whereas mutations in these genes have not been detected (Cancer Genome Atlas Research Network., 2011; 21720365). Inactivation of CDKN2A/B by promoter methylation, leading to loss of p16INK4a and p15INK4b expression, has been reported in ovarian cancer samples (Ozdemir et al., 2012; 23226780, Abou-Zeid et al., 2011; 21728901). Reduced expression of both CDKN2A mRNA and p16INK4a protein levels has been reported in 30% of epithelial ovarian tumors, but gene deletion accounted for very few to none of these cases (Fujita et al., 1997; 9133447, Niederacher et al., 1999; 10471040). Among low-grade tumors, loss of p16INK4a has been associated with the progression from borderline to low-grade invasive ovarian cancer, but p16INK4a expression in high-grade ovarian cancer has been reported to be variable (Schlosshauer et al., 2011; 21131838). Although earlier studies reported conflicting results on the association of p16INK4a expression and ovarian cancer prognosis (Bilyk et al., 2011; 21956468, Giordano et al., 2008; 18180113, Khouja et al., 2007; 17885492, Surowiak et al., 2008; 18283637, Lee et al., 2011; 21464733, Bali et al., 2004; 15297421), a large study of high-grade serous ovarian carcinoma concluded that homogeneous (high) p16INK4a expression and concurrent Rb positivity predict shorter patient survival (Milea et al., 2014; 24336157). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib (Fennell et al., 2022; 35157829) and palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889). However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. Germline CDKN2A mutation is associated with melanoma-pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma-astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>Homologous Recombination status</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>HRD Positive</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="HRD Positive" />
              </AlterationProperties>
              <Interpretation />
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>KMT2A (MLL)</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>amplification</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="true" name="amplification" />
              </AlterationProperties>
              <Interpretation>MLL (also known as KMT2A) encodes a histone methyltransferase, an enzyme involved in the modification of histones. It is involved in the positive regulation of transcription, particularly during development, although it is also expressed in most adult tissues (Marschalek, 2011; 21118195, Muntean and Hess, 2012; 22017583). MLL has been reported to be amplified in cancer, and may be biologically relevant in this context (Tang et al., 2015; 25387813, Andersen et al., 2001; 11284033, Dolan et al., 2002; 12034519). MLL amplification is rare in most solid tumors, occurring in &lt;2% of cases in most tumor types (cBioPortal, Apr 2023)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Published data investigating the prognostic implications of MLL alterations in ovarian, fallopian and peritoneal carcinomas are limited (PubMed, May 2023). Published data investigating the prognostic implications of KMT2A (MLL) alterations in solid tumors are limited (PubMed, Nov 2023). There are no targeted therapies available to address genomic mutations in or amplification of MLL.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>Microsatellite status</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>MS-Stable</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="MS-Stable" />
              </AlterationProperties>
              <Interpretation>Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA MMR in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI-high (MSI-H) has been reported in 1.6-19.7% of ovarian cancer samples (Segev et al., 2015; 26775351, Plisiecka-Hałasa et al., 2008; 18507046), including 3.8% (1/26) of ovarian endometrioid adenocarcinomas (Huang et al., 2015; 25195947), and 10.0% (3/30) of ovarian clear cell carcinomas (CCOCs) (Strickland et al., 2016; ASCO Abstract 5514). No association of MSI-H with stage or survival was found in patients with ovarian cancer (Segev et al., 2015; 26775351, Aysal et al., 2012; 22189970). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO-SITC Abstract P60).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>Tumor Mutation Burden</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>07</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="07" />
              </AlterationProperties>
              <Interpretation>Tumor mutational burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitutions and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide-based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD-1- or PD-L1-targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Ovarian carcinomas, including peritoneal and Fallopian tube carcinomas, harbor a median TMB of 2.7-3.6 Muts/Mb depending upon subtype, and up to 2.1% of cases have high TMB (&gt;20 Muts/Mb) (FMI-Chalmers et al., 2017; 28420421). In a study of high grade serous ovarian cancer, homologous recombination (HR)-deficient tumors, which comprised ~50% of all samples, harbored a higher neoantigen load compared to HR-proficient tumors; higher neoantigen load was associated with longer OS but not disease free survival (Strickland et al., 2016; 26871470). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti-PD-1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan-tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Ott et al., 2019; 30557521, Cristescu et al., 2022; 35101941, Friedman et al., 2022; 34876409, Sturgill et al., 2022; 35274716). In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB ≥10 Muts/Mb (as measured by this assay) compared with those with TMB &lt;10 Muts/Mb in a large cohort that included multiple tumor types (Marabelle et al., 2020; 32919526); similar findings were observed in the KEYNOTE 028 and 012 trials (Cristescu et al., 2018; 30309915). At the same TMB cutpoint, retrospective analysis of patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores ≥ 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores &lt;10 muts/Mb (HR=0.68) (Sturgill et al., 2022; 35274716). For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB ≥ 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples (Schenker at al., 2022; AACR Abstract 7845). However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan-solid tumors, where improved ORR and DCR was seen in patients with TMB ≥ 16 Muts/Mb than those with TMB ≥ 10 and &lt;16 Muts/Mb (Friedman et al., 2022; 34876409). Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as ≥16-20 Muts/Mb) achieved greater clinical benefit from PD-1 or PD-L1-targeting monotherapy compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD-1 or PD-L1-targeting agents (Goodman et al., 2017; 28835386).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
      </Genes>
      <Trials>
        <Trial>
          <Gene>Loss of Heterozygosity score</Gene>
          <Alteration>LOH-High</Alteration>
          <Title>Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>TROP2, PD-L1, PARP1, PD-1</Target>
          <Locations>Taipei (Taiwan), Taoyuan (Taiwan), Liou Ying Township (Taiwan), Hangzhou (China), Shanghai (China), Zhengzhou (China), Seoul (Korea, Republic of), Chongqing (China), Suita-shi (Japan), Nagoya-shi (Japan)</Locations>
          <NCTID>NCT05489211</NCTID>
          <Note>On the basis of emerging clinical data in ovarian cancer, elevated genomic LOH may be associated with greater sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Loss of Heterozygosity score</Gene>
          <Alteration>LOH-High</Alteration>
          <Title>IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>PARP</Target>
          <Locations>Taipei (Taiwan), Taoyuan (Taiwan), Taichung (Taiwan), Tainan (Taiwan), Wuhan (China), Gyeonggi-do (Korea, Republic of), Seoul (Korea, Republic of), Cheongju-si (Korea, Republic of), Beijing (China), Jilin (China)</Locations>
          <NCTID>NCT04434482</NCTID>
          <Note>On the basis of emerging clinical data in ovarian cancer, elevated genomic LOH may be associated with greater sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Loss of Heterozygosity score</Gene>
          <Alteration>LOH-High</Alteration>
          <Title>Phase I/IIa Study for AZD5335 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>PARP1</Target>
          <Locations>Tainan City (Taiwan), Tokyo (Japan), Melbourne (Australia), Haifa (Israel), Ramat Gan (Israel), California, Texas</Locations>
          <NCTID>NCT05797168</NCTID>
          <Note>On the basis of emerging clinical data in ovarian cancer, elevated genomic LOH may be associated with greater sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Loss of Heterozygosity score</Gene>
          <Alteration>LOH-High</Alteration>
          <Title>D9319C00001- 1L OC Mono Global RCT</Title>
          <StudyPhase>PHASE 3</StudyPhase>
          <Target>PARP</Target>
          <Locations>Wenzhou (China), Jiaxing (China), Shanghai (China), Suzhou (China), Wuxi (China), Nanjing (China), Hefei (China), Beijing (China), Changchun (China), Changsha (China)</Locations>
          <NCTID>NCT04884360</NCTID>
          <Note>On the basis of emerging clinical data in ovarian cancer, elevated genomic LOH may be associated with greater sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Loss of Heterozygosity score</Gene>
          <Alteration>LOH-High</Alteration>
          <Title>Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>RARA, PARP</Target>
          <Locations>Zhejiang (China)</Locations>
          <NCTID>NCT04518501</NCTID>
          <Note>On the basis of emerging clinical data in ovarian cancer, elevated genomic LOH may be associated with greater sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Loss of Heterozygosity score</Gene>
          <Alteration>LOH-High</Alteration>
          <Title>A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>PARP</Target>
          <Locations>Hangzhou (China)</Locations>
          <NCTID>NCT05489926</NCTID>
          <Note>On the basis of emerging clinical data in ovarian cancer, elevated genomic LOH may be associated with greater sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Loss of Heterozygosity score</Gene>
          <Alteration>LOH-High</Alteration>
          <Title>Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>PARP</Target>
          <Locations>Shanghai (China)</Locations>
          <NCTID>NCT03983226</NCTID>
          <Note>On the basis of emerging clinical data in ovarian cancer, elevated genomic LOH may be associated with greater sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Loss of Heterozygosity score</Gene>
          <Alteration>LOH-High</Alteration>
          <Title>Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PARP, PI3K-alpha</Target>
          <Locations>Shanghai (China)</Locations>
          <NCTID>NCT04586335</NCTID>
          <Note>On the basis of emerging clinical data in ovarian cancer, elevated genomic LOH may be associated with greater sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Loss of Heterozygosity score</Gene>
          <Alteration>LOH-High</Alteration>
          <Title>Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>PARP</Target>
          <Locations>Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Darlinghurst (Australia), Adana (Turkey), Jerusalem (Israel), Konya (Turkey), Ramat Gan (Israel), Istanbul (Turkey), Antalya (Turkey), Edirne (Turkey)</Locations>
          <NCTID>NCT03742895</NCTID>
          <Note>On the basis of emerging clinical data in ovarian cancer, elevated genomic LOH may be associated with greater sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>Loss of Heterozygosity score</Gene>
          <Alteration>LOH-High</Alteration>
          <Title>Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>ATR, PARP, PD-L1</Target>
          <Locations>Seoul (Korea, Republic of), Goyang-si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom), Villejuif (France)</Locations>
          <NCTID>NCT02264678</NCTID>
          <Note>On the basis of emerging clinical data in ovarian cancer, elevated genomic LOH may be associated with greater sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>TP53</Gene>
          <Alteration>R196*</Alteration>
          <Title>A Study of ZN-c3 in Patients With Platinum-Resistant Ovarian Cancer</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>WEE1</Target>
          <Locations>Busan (Korea, Republic of), Seoul (Korea, Republic of), Nedlands (Australia), Sunshine Coast (Australia), South Brisbane (Australia), Melbourne (Australia), Belgrade (Serbia), Tuzla (Bosnia and Herzegovina), Banja Luka (Bosnia and Herzegovina), Colorado</Locations>
          <NCTID>NCT04516447</NCTID>
          <Note>TP53 loss of function alterations may predict sensitivity to WEE1 inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>TP53</Gene>
          <Alteration>R196*</Alteration>
          <Title>Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>WEE1</Target>
          <Locations>Groningen (Netherlands), Nijmegen (Netherlands), Leiden (Netherlands), Barcelona (Spain)</Locations>
          <NCTID>NCT03968653</NCTID>
          <Note>TP53 loss of function alterations may predict sensitivity to WEE1 inhibitors.</Note>
          <Include>true</Include>
        </Trial>
      </Trials>
      <References>
        <Reference number="0">
          <ReferenceId>27908594</ReferenceId>
          <FullCitation>Swisher EM, et al. Lancet Oncol. (2017) pmid: 27908594</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="1">
          <ReferenceId>23047548</ReferenceId>
          <FullCitation>Abkevich V, et al. Br. J. Cancer (2012) pmid: 23047548</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="2">
          <ReferenceId>22912389</ReferenceId>
          <FullCitation>Wang ZC, et al. Clin. Cancer Res. (2012) pmid: 22912389</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="3">
          <ReferenceId>25093514</ReferenceId>
          <FullCitation>Watkins JA, et al. Breast Cancer Res. (2014) pmid: 25093514</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="4">
          <ReferenceId>28950147</ReferenceId>
          <FullCitation>Vanderstichele A, et al. Eur. J. Cancer (2017) pmid: 28950147</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="5">
          <ReferenceId>21720365</ReferenceId>
          <FullCitation>Nature (2011) pmid: 21720365</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="6">
          <ReferenceId>12736286</ReferenceId>
          <FullCitation>N. Engl. J. Med. (2003) pmid: 12736286</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="7">
          <ReferenceId>28916367</ReferenceId>
          <FullCitation>Coleman RL, et al. Lancet (2017) pmid: 28916367</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="8">
          <ReferenceId>26015868</ReferenceId>
          <FullCitation>Marquard AM, et al. Biomark Res (2015) pmid: 26015868</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="9">
          <ReferenceId>23716468</ReferenceId>
          <FullCitation>Pedersen BS, et al. Genes Chromosomes Cancer (2013) pmid: 23716468</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="10">
          <ReferenceId>27717299</ReferenceId>
          <FullCitation>Mirza MR, et al. N. Engl. J. Med. (2016) pmid: 27717299</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="11">
          <ReferenceId>26957554</ReferenceId>
          <FullCitation>Telli ML, et al. Clin. Cancer Res. (2016) pmid: 26957554</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="12">
          <ReferenceId>25475740</ReferenceId>
          <FullCitation>Timms KM, et al. Breast Cancer Res. (2014) pmid: 25475740</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="13">
          <ReferenceId>25847929</ReferenceId>
          <FullCitation>Telli ML, et al. J. Clin. Oncol. (2015) pmid: 25847929</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="14">
          <ReferenceId>25847936</ReferenceId>
          <FullCitation>Isakoff SJ, et al. J. Clin. Oncol. (2015) pmid: 25847936</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="15">
          <ReferenceId>19935675</ReferenceId>
          <FullCitation>Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="16">
          <ReferenceId>18410249</ReferenceId>
          <FullCitation>Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="17">
          <ReferenceId>12826609</ReferenceId>
          <FullCitation>Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="18">
          <ReferenceId>20978130</ReferenceId>
          <FullCitation>Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="19">
          <ReferenceId>28472496</ReferenceId>
          <FullCitation>Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="20">
          <ReferenceId>17690113</ReferenceId>
          <FullCitation>Yamada H, et al. Carcinogenesis (2007) pmid: 17690113</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="21">
          <ReferenceId>35120664</ReferenceId>
          <FullCitation>Nguyen B, et al. Cell (2022) pmid: 35120664</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="22">
          <ReferenceId>20229506</ReferenceId>
          <FullCitation>Ahmed AA, et al. J. Pathol. (2010) pmid: 20229506</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="23">
          <ReferenceId>23029043</ReferenceId>
          <FullCitation>Wojnarowicz PM, et al. PLoS ONE (2012) pmid: 23029043</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="24">
          <ReferenceId>19746182</ReferenceId>
          <FullCitation>Karst AM, et al. J Oncol (2010) pmid: 19746182</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="25">
          <ReferenceId>22304686</ReferenceId>
          <FullCitation>Gadducci A, et al. Gynecol. Endocrinol. (2012) pmid: 22304686</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="26">
          <ReferenceId>23965232</ReferenceId>
          <FullCitation>Rechsteiner M, et al. Exp. Mol. Pathol. (2013) pmid: 23965232</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="27">
          <ReferenceId>23765252</ReferenceId>
          <FullCitation>McConechy MK, et al. Mod. Pathol. (2014) pmid: 23765252</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="28">
          <ReferenceId>3178070</ReferenceId>
          <FullCitation>Mira Navarro J, et al. An Esp Pediatr (1988) pmid: 3178070</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="29">
          <ReferenceId>26257827</ReferenceId>
          <FullCitation>Ryland GL, et al. Genome Med (2015) pmid: 26257827</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="30">
          <ReferenceId>31477716</ReferenceId>
          <FullCitation>Cheasley D, et al. Nat Commun (2019) pmid: 31477716</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="31">
          <ReferenceId>33020491</ReferenceId>
          <FullCitation>Hollis RL, et al. Nat Commun (2020) pmid: 33020491</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="32">
          <ReferenceId>23558569</ReferenceId>
          <FullCitation>Altman AD, et al. Mod. Pathol. (2013) pmid: 23558569</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="33">
          <ReferenceId>23303020</ReferenceId>
          <FullCitation>Giurgea LN, et al. Rom J Morphol Embryol (2012) pmid: 23303020</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="34">
          <ReferenceId>17883046</ReferenceId>
          <FullCitation>Rajesh NG, et al. Indian J Pathol Microbiol (2007) pmid: 17883046</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="35">
          <ReferenceId>24071870</ReferenceId>
          <FullCitation>Lee S, et al. Int. J. Gynecol. Pathol. (2013) pmid: 24071870</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="36">
          <ReferenceId>19513073</ReferenceId>
          <FullCitation>de Graeff P, et al. Br. J. Cancer (2009) pmid: 19513073</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="37">
          <ReferenceId>20107315</ReferenceId>
          <FullCitation>Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="38">
          <ReferenceId>21799033</ReferenceId>
          <FullCitation>Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="39">
          <ReferenceId>21389100</ReferenceId>
          <FullCitation>Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="40">
          <ReferenceId>25504633</ReferenceId>
          <FullCitation>Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="41">
          <ReferenceId>12489850</ReferenceId>
          <FullCitation>Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="42">
          <ReferenceId>11713371</ReferenceId>
          <FullCitation>Xu L, et al. Mol. Med. (2001) pmid: 11713371</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="43">
          <ReferenceId>23470564</ReferenceId>
          <FullCitation>Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="44">
          <ReferenceId>25240597</ReferenceId>
          <FullCitation>Kim SS, et al. Nanomedicine (2015) pmid: 25240597</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="45">
          <ReferenceId>27357628</ReferenceId>
          <FullCitation>Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="46">
          <ReferenceId>27601554</ReferenceId>
          <FullCitation>Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="47">
          <ReferenceId>37236033</ReferenceId>
          <FullCitation>Embaby A, et al. Gynecol Oncol (2023) pmid: 37236033</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="48">
          <ReferenceId>31315834</ReferenceId>
          <FullCitation>Lee J, et al. Cancer Discov (2019) pmid: 31315834</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="49">
          <ReferenceId>29535125</ReferenceId>
          <FullCitation>Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="50">
          <ReferenceId>34538072</ReferenceId>
          <FullCitation>Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="51">
          <ReferenceId>36084396</ReferenceId>
          <FullCitation>Park H, et al. ESMO Open (2022) pmid: 36084396</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="52">
          <ReferenceId>29165669</ReferenceId>
          <FullCitation>Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="53">
          <ReferenceId>26014290</ReferenceId>
          <FullCitation>Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="54">
          <ReferenceId>23355100</ReferenceId>
          <FullCitation>Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="55">
          <ReferenceId>11219776</ReferenceId>
          <FullCitation>Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="56">
          <ReferenceId>9006316</ReferenceId>
          <FullCitation>Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="57">
          <ReferenceId>19204208</ReferenceId>
          <FullCitation>Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="58">
          <ReferenceId>12672316</ReferenceId>
          <FullCitation>Lalloo F, et al. Lancet (2003) pmid: 12672316</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="59">
          <ReferenceId>31050713</ReferenceId>
          <FullCitation>Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="60">
          <ReferenceId>25426837</ReferenceId>
          <FullCitation>Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="61">
          <ReferenceId>25426838</ReferenceId>
          <FullCitation>Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="62">
          <ReferenceId>25326804</ReferenceId>
          <FullCitation>Xie M, et al. Nat. Med. (2014) pmid: 25326804</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="63">
          <ReferenceId>28669404</ReferenceId>
          <FullCitation>Acuna-Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="64">
          <ReferenceId>29678827</ReferenceId>
          <FullCitation>Severson EA, et al. Blood (2018) pmid: 29678827</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="65">
          <ReferenceId>29420212</ReferenceId>
          <FullCitation>Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="66">
          <ReferenceId>30504320</ReferenceId>
          <FullCitation>Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="67">
          <ReferenceId>32269342</ReferenceId>
          <FullCitation>Chabon JJ, et al. Nature (2020) pmid: 32269342</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="68">
          <ReferenceId>31768066</ReferenceId>
          <FullCitation>Razavi P, et al. Nat. Med. (2019) pmid: 31768066</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="69">
          <ReferenceId>26337942</ReferenceId>
          <FullCitation>Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="70">
          <ReferenceId>21081928</ReferenceId>
          <FullCitation>You JF, et al. Br. J. Cancer (2010) pmid: 21081928</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="71">
          <ReferenceId>24623249</ReferenceId>
          <FullCitation>Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="72">
          <ReferenceId>9823339</ReferenceId>
          <FullCitation>Boland CR, et al. Cancer Res. (1998) pmid: 9823339</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="73">
          <ReferenceId>15528785</ReferenceId>
          <FullCitation>Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="74">
          <ReferenceId>20420947</ReferenceId>
          <FullCitation>Boland CR, et al. Gastroenterology (2010) pmid: 20420947</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="75">
          <ReferenceId>26775351</ReferenceId>
          <FullCitation>Segev Y, et al. Eur. J. Gynaecol. Oncol. (2015) pmid: 26775351</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="76">
          <ReferenceId>18507046</ReferenceId>
          <FullCitation>Plisiecka-Hałasa J, et al. Anticancer Res. () pmid: 18507046</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="77">
          <ReferenceId>25195947</ReferenceId>
          <FullCitation>Huang HN, et al. Histopathology (2015) pmid: 25195947</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="78">
          <ReferenceId>22189970</ReferenceId>
          <FullCitation>Aysal A, et al. Am. J. Surg. Pathol. (2012) pmid: 22189970</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="79">
          <ReferenceId>25392179</ReferenceId>
          <FullCitation>Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="80">
          <ReferenceId>26140250</ReferenceId>
          <FullCitation>Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="81">
          <ReferenceId>25949894</ReferenceId>
          <FullCitation>Lal N, et al. Oncoimmunology (2015) pmid: 25949894</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="82">
          <ReferenceId>26028255</ReferenceId>
          <FullCitation>Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="83">
          <ReferenceId>21118195</ReferenceId>
          <FullCitation>Br. J. Haematol. (2011) pmid: 21118195</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="84">
          <ReferenceId>22017583</ReferenceId>
          <FullCitation>Muntean AG, et al. Annu Rev Pathol (2012) pmid: 22017583</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="85">
          <ReferenceId>25387813</ReferenceId>
          <FullCitation>Tang G, et al. Hum. Pathol. (2015) pmid: 25387813</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="86">
          <ReferenceId>11284033</ReferenceId>
          <FullCitation>Andersen MK, et al. Genes Chromosomes Cancer (2001) pmid: 11284033</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="87">
          <ReferenceId>12034519</ReferenceId>
          <FullCitation>Dolan M, et al. Cancer Genet. Cytogenet. (2002) pmid: 12034519</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="88">
          <ReferenceId>22588877</ReferenceId>
          <FullCitation>Cerami E, et al. Cancer Discov (2012) pmid: 22588877</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="89">
          <ReferenceId>23550210</ReferenceId>
          <FullCitation>Gao J, et al. Sci Signal (2013) pmid: 23550210</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="90">
          <ReferenceId>8521522</ReferenceId>
          <FullCitation>Quelle DE, et al. Cell (1995) pmid: 8521522</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="91">
          <ReferenceId>15878778</ReferenceId>
          <FullCitation>Mutat. Res. (2005) pmid: 15878778</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="92">
          <ReferenceId>9484839</ReferenceId>
          <FullCitation>Gazzeri S, et al. Oncogene (1998) pmid: 9484839</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="93">
          <ReferenceId>10498883</ReferenceId>
          <FullCitation>Oncogene (1999) pmid: 10498883</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="94">
          <ReferenceId>16869746</ReferenceId>
          <FullCitation>Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="95">
          <ReferenceId>20549699</ReferenceId>
          <FullCitation>Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="96">
          <ReferenceId>10498896</ReferenceId>
          <FullCitation>Ruas M, et al. Oncogene (1999) pmid: 10498896</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="97">
          <ReferenceId>17909018</ReferenceId>
          <FullCitation>Jones R, et al. Cancer Res. (2007) pmid: 17909018</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="98">
          <ReferenceId>18843795</ReferenceId>
          <FullCitation>Haferkamp S, et al. Aging Cell (2008) pmid: 18843795</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="99">
          <ReferenceId>12417717</ReferenceId>
          <FullCitation>Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="100">
          <ReferenceId>11518711</ReferenceId>
          <FullCitation>Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="101">
          <ReferenceId>9324288</ReferenceId>
          <FullCitation>Gombart AF, et al. Leukemia (1997) pmid: 9324288</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="102">
          <ReferenceId>7780957</ReferenceId>
          <FullCitation>Yang R, et al. Cancer Res. (1995) pmid: 7780957</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="103">
          <ReferenceId>8668202</ReferenceId>
          <FullCitation>Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="104">
          <ReferenceId>12606942</ReferenceId>
          <FullCitation>Greenblatt MS, et al. Oncogene (2003) pmid: 12606942</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="105">
          <ReferenceId>10491434</ReferenceId>
          <FullCitation>Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="106">
          <ReferenceId>11255261</ReferenceId>
          <FullCitation>Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="107">
          <ReferenceId>9660926</ReferenceId>
          <FullCitation>Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="108">
          <ReferenceId>19260062</ReferenceId>
          <FullCitation>Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="109">
          <ReferenceId>10719365</ReferenceId>
          <FullCitation>Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="110">
          <ReferenceId>7777061</ReferenceId>
          <FullCitation>Koh J, et al. Nature (1995) pmid: 7777061</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="111">
          <ReferenceId>20340136</ReferenceId>
          <FullCitation>McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="112">
          <ReferenceId>21462282</ReferenceId>
          <FullCitation>Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="113">
          <ReferenceId>905385</ReferenceId>
          <FullCitation>Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="114">
          <ReferenceId>24659262</ReferenceId>
          <FullCitation>Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="115">
          <ReferenceId>23190892</ReferenceId>
          <FullCitation>Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="116">
          <ReferenceId>10389768</ReferenceId>
          <FullCitation>Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="117">
          <ReferenceId>12853981</ReferenceId>
          <FullCitation>Rutter JL, et al. Oncogene (2003) pmid: 12853981</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="118">
          <ReferenceId>30371878</ReferenceId>
          <FullCitation>Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="119">
          <ReferenceId>23226780</ReferenceId>
          <FullCitation>Ozdemir F, et al. Exp Ther Med (2012) pmid: 23226780</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="120">
          <ReferenceId>21728901</ReferenceId>
          <FullCitation>Abou-Zeid AA, et al. Scand. J. Clin. Lab. Invest. (2011) pmid: 21728901</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="121">
          <ReferenceId>9133447</ReferenceId>
          <FullCitation>Fujita M, et al. Int. J. Cancer (1997) pmid: 9133447</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="122">
          <ReferenceId>10471040</ReferenceId>
          <FullCitation>Niederacher D, et al. Br. J. Cancer (1999) pmid: 10471040</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="123">
          <ReferenceId>21131838</ReferenceId>
          <FullCitation>Schlosshauer PW, et al. Int. J. Gynecol. Pathol. (2011) pmid: 21131838</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="124">
          <ReferenceId>21956468</ReferenceId>
          <FullCitation>Bilyk OO, et al. Exp. Oncol. (2011) pmid: 21956468</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="125">
          <ReferenceId>18180113</ReferenceId>
          <FullCitation>Giordano G, et al. Pathol. Res. Pract. (2008) pmid: 18180113</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="126">
          <ReferenceId>17885492</ReferenceId>
          <FullCitation>Khouja MH, et al. Int. J. Gynecol. Pathol. (2007) pmid: 17885492</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="127">
          <ReferenceId>18283637</ReferenceId>
          <FullCitation>Surowiak P, et al. Histol. Histopathol. (2008) pmid: 18283637</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="128">
          <ReferenceId>21464733</ReferenceId>
          <FullCitation>Lee YH, et al. Int. J. Gynecol. Pathol. (2011) pmid: 21464733</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="129">
          <ReferenceId>15297421</ReferenceId>
          <FullCitation>Bali A, et al. Clin. Cancer Res. (2004) pmid: 15297421</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="130">
          <ReferenceId>24336157</ReferenceId>
          <FullCitation>Milea A, et al. Mod. Pathol. (2014) pmid: 24336157</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="131">
          <ReferenceId>21278246</ReferenceId>
          <FullCitation>Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="132">
          <ReferenceId>21871868</ReferenceId>
          <FullCitation>Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="133">
          <ReferenceId>22711607</ReferenceId>
          <FullCitation>Cen L, et al. Neuro-oncology (2012) pmid: 22711607</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="134">
          <ReferenceId>23898052</ReferenceId>
          <FullCitation>Logan JE, et al. Anticancer Res. (2013) pmid: 23898052</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="135">
          <ReferenceId>35157829</ReferenceId>
          <FullCitation>Fennell DA, et al. Lancet Oncol (2022) pmid: 35157829</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="136">
          <ReferenceId>28283584</ReferenceId>
          <FullCitation>Elvin JA, et al. Oncologist (2017) pmid: 28283584</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="137">
          <ReferenceId>26715889</ReferenceId>
          <FullCitation>Gao J, et al. Curr Oncol (2015) pmid: 26715889</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="138">
          <ReferenceId>25501126</ReferenceId>
          <FullCitation>DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="139">
          <ReferenceId>25524798</ReferenceId>
          <FullCitation>Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="140">
          <ReferenceId>27542767</ReferenceId>
          <FullCitation>Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="141">
          <ReferenceId>24797823</ReferenceId>
          <FullCitation>Johnson DB, et al. Oncologist (2014) pmid: 24797823</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="142">
          <ReferenceId>7666917</ReferenceId>
          <FullCitation>Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="143">
          <ReferenceId>20687502</ReferenceId>
          <FullCitation>Adv Exp Med Biol (2010) pmid: 20687502</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="144">
          <ReferenceId>9479083</ReferenceId>
          <FullCitation>Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="145">
          <ReferenceId>29543703</ReferenceId>
          <FullCitation>De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="146">
          <ReferenceId>26892650</ReferenceId>
          <FullCitation>Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="147">
          <ReferenceId>29405243</ReferenceId>
          <FullCitation>Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="148">
          <ReferenceId>8414022</ReferenceId>
          <FullCitation>Kaufman DK, et al. Neurology (1993) pmid: 8414022</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="149">
          <ReferenceId>9622062</ReferenceId>
          <FullCitation>Bahuau M, et al. Cancer Res (1998) pmid: 9622062</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="150">
          <ReferenceId>28699883</ReferenceId>
          <FullCitation>Chan AK, et al. Clin Neuropathol () pmid: 28699883</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="151">
          <ReferenceId>15748635</ReferenceId>
          <FullCitation>Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="152">
          <ReferenceId>23875803</ReferenceId>
          <FullCitation>Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="153">
          <ReferenceId>12379884</ReferenceId>
          <FullCitation>Pfeifer GP, et al. Oncogene (2002) pmid: 12379884</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="154">
          <ReferenceId>25765070</ReferenceId>
          <FullCitation>Rizvi NA, et al. Science (2015) pmid: 25765070</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="155">
          <ReferenceId>24336570</ReferenceId>
          <FullCitation>Johnson BE, et al. Science (2014) pmid: 24336570</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="156">
          <ReferenceId>29452419</ReferenceId>
          <FullCitation>Choi S, et al. Neuro-oncology (2018) pmid: 29452419</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="157">
          <ReferenceId>23636398</ReferenceId>
          <FullCitation>Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="158">
          <ReferenceId>23447401</ReferenceId>
          <FullCitation>Briggs S, et al. J. Pathol. (2013) pmid: 23447401</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="159">
          <ReferenceId>24583393</ReferenceId>
          <FullCitation>Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="160">
          <ReferenceId>22810696</ReferenceId>
          <FullCitation>Nature (2012) pmid: 22810696</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="161">
          <ReferenceId>25568919</ReferenceId>
          <FullCitation>Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="162">
          <ReferenceId>28835386</ReferenceId>
          <FullCitation>Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="163">
          <ReferenceId>32919526</ReferenceId>
          <FullCitation>Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="164">
          <ReferenceId>31405947</ReferenceId>
          <FullCitation>Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="165">
          <ReferenceId>28420421</ReferenceId>
          <FullCitation>Chalmers ZR, et al. Genome Med (2017) pmid: 28420421</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="166">
          <ReferenceId>26871470</ReferenceId>
          <FullCitation>Strickland KC, et al. Oncotarget (2016) pmid: 26871470</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="167">
          <ReferenceId>30643254</ReferenceId>
          <FullCitation>Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="168">
          <ReferenceId>30309915</ReferenceId>
          <FullCitation>Cristescu R, et al. Science (2018) pmid: 30309915</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="169">
          <ReferenceId>30785829</ReferenceId>
          <FullCitation>Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="170">
          <ReferenceId>29658845</ReferenceId>
          <FullCitation>Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="171">
          <ReferenceId>29657128</ReferenceId>
          <FullCitation>Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="172">
          <ReferenceId>29731394</ReferenceId>
          <FullCitation>Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="173">
          <ReferenceId>33558721</ReferenceId>
          <FullCitation>Rozeman EA, et al. Nat Med (2021) pmid: 33558721</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="174">
          <ReferenceId>32916128</ReferenceId>
          <FullCitation>Sharma P, et al. Cancer Cell (2020) pmid: 32916128</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="175">
          <ReferenceId>30557521</ReferenceId>
          <FullCitation>Ott PA, et al. J. Clin. Oncol. (2019) pmid: 30557521</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="176">
          <ReferenceId>35101941</ReferenceId>
          <FullCitation>Cristescu R, et al. J Immunother Cancer (2022) pmid: 35101941</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="177">
          <ReferenceId>34876409</ReferenceId>
          <FullCitation>Friedman CF, et al. Cancer Discov (2022) pmid: 34876409</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="178">
          <ReferenceId>35274716</ReferenceId>
          <FullCitation>Sturgill EG, et al. Oncologist (2022) pmid: 35274716</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="179">
          <ReferenceId>35658487</ReferenceId>
          <FullCitation>Monk BJ, et al. J Clin Oncol (2022) pmid: 35658487</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="180">
          <ReferenceId>30638768</ReferenceId>
          <FullCitation>Fabbro M, et al. Gynecol. Oncol. (2019) pmid: 30638768</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="181">
          <ReferenceId>31562799</ReferenceId>
          <FullCitation>González-Martín A, et al. N. Engl. J. Med. (2019) pmid: 31562799</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="182">
          <ReferenceId>30948273</ReferenceId>
          <FullCitation>Moore KN, et al. Lancet Oncol. (2019) pmid: 30948273</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="183">
          <ReferenceId>31474354</ReferenceId>
          <FullCitation>Mirza MR, et al. Lancet Oncol. (2019) pmid: 31474354</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="184">
          <ReferenceId>31194228</ReferenceId>
          <FullCitation>Konstantinopoulos PA, et al. JAMA Oncol (2019) pmid: 31194228</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="185">
          <ReferenceId>31851799</ReferenceId>
          <FullCitation>Ray-Coquard I, et al. N Engl J Med (2019) pmid: 31851799</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="186">
          <ReferenceId>25481791</ReferenceId>
          <FullCitation>Oza AM, et al. Lancet Oncol. (2015) pmid: 25481791</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="187">
          <ReferenceId>25218906</ReferenceId>
          <FullCitation>Liu JF, et al. Lancet Oncol. (2014) pmid: 25218906</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="188">
          <ReferenceId>35290101</ReferenceId>
          <FullCitation>Liu JF, et al. J Clin Oncol (2022) pmid: 35290101</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="189">
          <ReferenceId>19553641</ReferenceId>
          <FullCitation>Fong PC, et al. N. Engl. J. Med. (2009) pmid: 19553641</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="190">
          <ReferenceId>21862407</ReferenceId>
          <FullCitation>Gelmon KA, et al. Lancet Oncol. (2011) pmid: 21862407</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="191">
          <ReferenceId>26723501</ReferenceId>
          <FullCitation>Domchek SM, et al. Gynecol. Oncol. (2016) pmid: 26723501</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="192">
          <ReferenceId>26961146</ReferenceId>
          <FullCitation>Matulonis UA, et al. Ann. Oncol. (2016) pmid: 26961146</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="193">
          <ReferenceId>20406929</ReferenceId>
          <FullCitation>Fong PC, et al. J. Clin. Oncol. (2010) pmid: 20406929</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="194">
          <ReferenceId>30345884</ReferenceId>
          <FullCitation>Moore K, et al. N. Engl. J. Med. (2018) pmid: 30345884</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="195">
          <ReferenceId>33743851</ReferenceId>
          <FullCitation>Poveda A, et al. Lancet Oncol (2021) pmid: 33743851</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="196">
          <ReferenceId>28754483</ReferenceId>
          <FullCitation>Pujade-Lauraine E, et al. Lancet Oncol. (2017) pmid: 28754483</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="197">
          <ReferenceId>27617661</ReferenceId>
          <FullCitation>Ledermann JA, et al. Lancet Oncol. (2016) pmid: 27617661</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="198">
          <ReferenceId>22452356</ReferenceId>
          <FullCitation>Ledermann J, et al. N. Engl. J. Med. (2012) pmid: 22452356</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="199">
          <ReferenceId>24882434</ReferenceId>
          <FullCitation>Ledermann J, et al. Lancet Oncol. (2014) pmid: 24882434</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="200">
          <ReferenceId>36082969</ReferenceId>
          <FullCitation>DiSilvestro P, et al. J Clin Oncol (2022) pmid: 36082969</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="201">
          <ReferenceId>37030280</ReferenceId>
          <FullCitation>Pignata S, et al. Gynecol Oncol (2023) pmid: 37030280</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="202">
          <ReferenceId>28242752</ReferenceId>
          <FullCitation>de Bono J, et al. Cancer Discov (2017) pmid: 28242752</FullCitation>
          <Include>true</Include>
        </Reference>
      </References>
      <Signatures>
        <Signature>
          <ServerTime>2024-01-18 20:32:55</ServerTime>
          <OpName>Erik Williams, M.D. | Lauren L. Ritterhouse Casariego, M.D., Ph.D., Laboratory Director</OpName>
          <Text>Erik Williams, M.D. | Lauren L. Ritterhouse Casariego, M.D., Ph.D., Laboratory Director</Text>
        </Signature>
      </Signatures>
      <reportProperties>
        <reportProperty identifier="QualityControlMetrics" key="MedianCoverageValue">
          <value>836x</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="TumorMutationBurdenScore">
          <value>7 Muts/Mb</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="MicrosatelliteStatusScore">
          <value>0 fraction-unstable-loci</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="LossOfHeterozygosityScore">
          <value>28.3%</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="BloodTumorMutationalBurdenScore">
          <value>Units Not Reported</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="TumorFractionScore">
          <value>Units Not Reported</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="ComprehensiveTumorFractionScore">
          <value>Units Not Reported</value>
        </reportProperty>
      </reportProperties>
      <comments />
      <AAC>
        <Amendmends />
      </AAC>
    </FinalReport>
    <variant-report xmlns="http://foundationmedicine.com/compbio/variant-report-external" disease="PERITONEUM" disease-ontology="Peritoneum serous carcinoma" flowcell-analysis="2000033275" gender="female" pathology-diagnosis="Peritoneum serous carcinoma" percent-tumor-nuclei="40" pipeline-version="v3.29.0" purity-assessment="58.77" specimen="ORD-1795940-01*US1710200.01" study="CLINICAL-F1CDx v2" test-request="ORD-1795940-01" test-type="FoundationOneDx" tissue-of-origin="Omentum" xsi:schemaLocation="http://foundationmedicine.com/compbio/variant-report-external http://integration.foundationmedicine.com/reporting/variant-report-external-2.2.xsd">
      <samples>
        <sample bait-set="DX2" mean-exon-depth="882.5" name="SQ-US1710200.01-1" nucleic-acid-type="DNA" />
      </samples>
      <quality-control status="Pass" />
      <short-variants>
        <short-variant allele-fraction="0.326" cds-effect="9742_9752delGTGGTTTCTAA" depth="2043" equivocal="false" functional-effect="frameshift" gene="MLL" percent-reads="32.6" position="chr11:118376357" protein-effect="V3248fs*5" status="unknown" strand="+" transcript="NM_005933">
          <dna-evidence sample="SQ-US1710200.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.748" cds-effect="241C&gt;T" depth="623" equivocal="false" functional-effect="missense" gene="AURKB" percent-reads="74.8" position="chr17:8110651" protein-effect="R81C" status="unknown" strand="-" transcript="NM_004217">
          <dna-evidence sample="SQ-US1710200.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.4812" cds-effect="1697T&gt;C" depth="960" equivocal="false" functional-effect="missense" gene="NTRK1" percent-reads="48.12" position="chr1:156846256" protein-effect="M566T" status="unknown" strand="+" transcript="NM_002529">
          <dna-evidence sample="SQ-US1710200.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.6204" cds-effect="586C&gt;T" depth="1022" equivocal="false" functional-effect="nonsense" gene="TP53" percent-reads="62.04" position="chr17:7578263" protein-effect="R196*" status="known" strand="-" transcript="NM_000546">
          <dna-evidence sample="SQ-US1710200.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.6654" cds-effect="1734G&gt;C" depth="514" equivocal="false" functional-effect="missense" gene="ARAF" percent-reads="66.54" position="chrX:47430769" protein-effect="E578D" status="unknown" strand="+" transcript="NM_001654">
          <dna-evidence sample="SQ-US1710200.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.5782" cds-effect="682G&gt;A" depth="1164" equivocal="false" functional-effect="missense" gene="BRD4" percent-reads="57.82" position="chr19:15376332" protein-effect="V228I" status="unknown" strand="-" transcript="NM_014299">
          <dna-evidence sample="SQ-US1710200.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.6799" cds-effect="4094C&gt;T" depth="653" equivocal="false" functional-effect="missense" gene="KDM5C" percent-reads="67.99" position="chrX:53222978" protein-effect="P1365L" status="unknown" strand="-" transcript="NM_004187">
          <dna-evidence sample="SQ-US1710200.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.0942" cds-effect="-38_26del64" depth="796" equivocal="false" functional-effect="nonsense" gene="EGFR" percent-reads="9.42" position="chr7:55086932" protein-effect="M1?" status="unknown" strand="+" transcript="NM_005228">
          <dna-evidence sample="SQ-US1710200.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.6432" cds-effect="1736G&gt;A" depth="782" equivocal="false" functional-effect="missense" gene="KDM6A" percent-reads="64.32" position="chrX:44922875" protein-effect="C579Y" status="unknown" strand="+" transcript="NM_021140">
          <dna-evidence sample="SQ-US1710200.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.5053" cds-effect="12143C&gt;T" depth="1215" equivocal="false" functional-effect="missense" gene="MLL2" percent-reads="50.53" position="chr12:49426345" protein-effect="P4048L" status="unknown" strand="-" transcript="NM_003482">
          <dna-evidence sample="SQ-US1710200.01-1" />
        </short-variant>
      </short-variants>
      <copy-number-alterations>
        <copy-number-alteration copy-number="9" equivocal="true" gene="CHEK1" number-of-exons="12 of 12" position="chr11:125496631-125525231" ratio="1.97" status="unknown" type="amplification">
          <dna-evidence sample="SQ-US1710200.01-1" />
        </copy-number-alteration>
        <copy-number-alteration copy-number="8" equivocal="true" gene="MLL" number-of-exons="36 of 36" position="chr11:118307227-118392887" ratio="2.02" status="known" type="amplification">
          <dna-evidence sample="SQ-US1710200.01-1" />
        </copy-number-alteration>
        <copy-number-alteration copy-number="0" equivocal="false" gene="CDKN2A" number-of-exons="1 of 5" position="chr9:21974475-21974826" ratio="0.38" status="known" type="loss">
          <dna-evidence sample="SQ-US1710200.01-1" />
        </copy-number-alteration>
      </copy-number-alterations>
      <rearrangements />
      <biomarkers>
        <microsatellite-instability status="MSS" />
        <tumor-mutation-burden score="7.24" status="intermediate" unit="mutations-per-megabase" />
      </biomarkers>
      <non-human-content />
    </variant-report>
  </rr:ResultsPayload>
</rr:ResultsReport>
